Clinical Trials
Phesi analysis shows difference of up to three months in current COVID-19 vaccine trial recruitment
Analysis from virtual clinical development specialist Phesi shows the enrollment and effectiveness of two current COVID-19 vaccine trials conducted by global pharmaceutical development companies. On the surface, both trials appear to be on track to complete enrollment, however, looking...
News
RDIF and Uniao Quimica file documents for registration of Sputnik V vaccine with regulator in Brazil
The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), União QuÃmica Farmacêutica Nacional and the Government of the State of Paraná announce the pre-submission of preliminary documents to Brazil's National Health Surveillance Agency (ANVISA), in order to register...
Clinical Trials
Tiziana begins study of nasally administered Foralumab either alone or in combo with dexamethasone to treat COVID-19 in Brazil
Tiziana Life Sciences, a biotechnology company, announced initiation of a collaborative clinical study investigating nasally administered Foralumab either alone or in combination with orally administered dexamethasone in COVID-19 patients in Brazil. In view of the importance and urgency, scientific...
News
BERG Creates Collaborative Healthcare Model to Transform the Future of Drug Development
Partners across multiple healthcare divisions join forces to break down siloes to accelerate precision medicine opportunities for COVID-19 and beyond BERG, a clinical-stage biotech that employs artificial intelligence (AI) to investigate diseases and develop innovative treatments, announced a new...
Clinical Trials
Mayo Clinic Collaborates with Vocalis Health for Clinical Development of Vocal Biomarkers
Mayo Clinic and Vocalis Health, Inc., a company pioneering AI-based vocal biomarkers for use in healthcare, announced a collaboration to research and develop new voice-based tools for screening, detecting and monitoring patient health. The collaboration will begin with a...
Clinical Trials
Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira in Moderate-to-Severe Psoriasis Patients
UCB, a global biopharmaceutical company, announced the detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults...
News
EC approves Roches Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Roche announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
“Tecentriq in combination with Avastin...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read